RNA Splicing Correction Therapy: Mechanisms, Clinical Applications, and Future Directions

Abstract

RNA splicing correction therapy has emerged as a groundbreaking molecular approach for treating genetic disorders caused by aberrant pre-mRNA splicing. This review synthesizes recent evidence, clinical advances, and mechanistic insights, emphasizing its clinical relevance, therapeutic potential, and future prospects. We discuss the underlying pathophysiology, epidemiological significance, risk factors, diagnostic strategies, therapeutic modalities, and current guideline recommendations, providing an expert resource for healthcare professionals.

Introduction

Splicing defects in pre-messenger RNA (pre-mRNA) are a significant cause of inherited and acquired diseases, including various neuromuscular, hematological, and metabolic disorders. RNA splicing correction therapies attempt to restore normal gene expression by modulating the splicing machinery or correcting specific splicing errors. With advances in molecular biology and the approval of splice-modulating drugs, this therapeutic strategy has rapidly gained traction in clinical practice and research. This article aims to provide healthcare professionals with a comprehensive overview of RNA splicing correction therapy, focusing on its mechanisms, clinical applications, and future directions.

Epidemiology / Disease Burden

Aberrant RNA splicing underlies a vast array of human diseases. It is estimated that approximately 15–60% of all disease-causing mutations affect pre-mRNA splicing. Disorders such as spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), cystic fibrosis, and certain β-thalassemias have well-established links to splicing errors. The prevalence of these conditions collectively contributes to a substantial disease burden worldwide, with significant morbidity and mortality, especially in pediatric populations. Accurate epidemiological assessment is complicated by underdiagnosis and genetic heterogeneity, yet the clinical impact of splicing-related pathologies remains profound.

Pathophysiology

Pre-mRNA splicing is a highly regulated process by which introns are removed and exons are joined to form mature messenger RNA (mRNA). This process is orchestrated by the spliceosome, a complex of small nuclear ribonucleoproteins (snRNPs) and associated proteins. Mutations affecting canonical splice sites, branch points, or splicing regulatory elements can disrupt normal exon-intron architecture, resulting in exon skipping, intron retention, or cryptic splice site activation. These aberrations produce defective or truncated proteins, thereby driving disease phenotype. The detailed understanding of splicing mechanisms has enabled the rational design of therapies aimed at correcting these molecular defects.

Risk Factors

Genetic factors remain the primary risk determinant for splicing-related disorders. Mutations in exonic or intronic splicing motifs, as well as in trans-acting splicing factors, can predispose individuals to aberrant mRNA processing. In addition, epigenetic modifications, RNA secondary structures, and environmental exposures (such as oxidative stress and certain drugs) may modulate splicing fidelity. Family history, consanguinity, and specific ethnic backgrounds also increase the risk of splicing disorders, emphasizing the need for genetic counseling in high-risk populations.

Clinical Features

The clinical phenotype of splicing disorders is diverse, reflecting the tissue distribution and function of the affected gene product. For example, SMA is characterized by progressive muscular weakness and atrophy due to SMN1 gene splicing defects, while DMD presents with muscle degeneration caused by dystrophin gene exon skipping. β-thalassemias typically manifest as anemia and ineffective erythropoiesis, often linked to abnormal splicing of the β-globin gene. The variable expressivity and penetrance of splicing mutations can result in a spectrum of clinical severity, complicating diagnosis and management.

Diagnosis

Diagnosis of splicing disorders relies on a combination of clinical evaluation, genetic testing, and molecular analysis. Next-generation sequencing (NGS) and RNA sequencing (RNA-seq) have revolutionized the identification of splicing mutations and their functional consequences. Functional assays, such as minigene reporter systems and in vitro splicing assays, are utilized to validate the impact of suspected variants. Additionally, transcriptomic profiling can reveal aberrant splicing patterns, guiding diagnostic and therapeutic decisions. Early and accurate diagnosis is critical for timely intervention, particularly as splicing-modulating therapies become more available.

Treatment & Management

RNA splicing correction therapy encompasses a range of strategies aimed at restoring normal splicing and protein function. Antisense oligonucleotides (ASOs) represent the most advanced approach, with FDA-approved drugs such as nusinersen for SMA and eteplirsen for DMD. These synthetic molecules bind specific RNA sequences to modulate exon inclusion or exclusion, thereby correcting the splicing defect. Other modalities include small molecules that modify spliceosome activity, RNA trans-splicing, and gene editing tools like CRISPR/Cas9. Supportive care, physical therapy, and multidisciplinary management remain essential components of care for affected patients.

Recent Advances / Emerging Therapies

Recent years have witnessed remarkable progress in splicing correction technologies. Next-generation ASOs are being optimized for improved tissue targeting, stability, and reduced immunogenicity. Small molecule splicing modulators, such as risdiplam for SMA, offer oral administration and favorable pharmacokinetics. Gene therapy approaches leveraging adeno-associated virus (AAV) vectors for in vivo delivery of splicing factors are under active investigation. CRISPR-based RNA targeting and base editing technologies hold promise for precise, durable correction of splicing mutations. Ongoing clinical trials are evaluating these novel therapies across a spectrum of genetic diseases, heralding a new era of personalized medicine.

Guideline Recommendations

Current clinical guidelines emphasize early genetic diagnosis, multidisciplinary care, and timely initiation of splicing correction therapy where approved. The American Academy of Neurology and the European Medicines Agency recommend nusinersen or risdiplam as first-line therapies for eligible SMA patients. Expert consensus supports the use of ASOs in DMD patients with confirmed amenable mutations. For other conditions, treatment remains investigational, and patients are best managed within clinical trial frameworks. Robust long-term follow-up and post-marketing surveillance are essential to monitor efficacy, safety, and emerging resistance.

Conclusion

RNA splicing correction therapy represents a transformative advance in molecular medicine, offering targeted treatment for previously intractable genetic disorders. Ongoing research continues to refine these approaches, expand their applicability, and address challenges related to delivery, specificity, and durability. Clinicians should remain abreast of evolving guidelines and evidence to optimize patient outcomes. As our understanding deepens and technology advances, RNA splicing correction is poised to play an increasingly central role in precision therapeutics.